

Supplementary Table 1. Immunogenicity of maintenance anti-TNF therapy in IBD RCTs.

RCT	Total ADA, %	With IMM, %	Without IMM, %
<i>Infliximab</i>			
[1]	7.3	0.9	14.6
[2]	14	9.7	17.2
[3]	17	9	21.3
<i>Adalimumab</i>			
[4]	0.4	0	0.4
[5]	2.6	0	3.8
[6]	2.9	0	2.9
<i>Certolizumab pegol</i>			
[7]	8	4	10
[8]	8	2	12
<i>Golimumab</i>			
[9]	2.9	1.1	3.8

TNF: tumor necrosis factor, RCTs: randomized control trials, ADA: anti-drug antibodies, IMM: immunomodulators, IBD: inflammatory bowel disease.

Supplementary references

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010;362:1383-95.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;359:1541-9.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med* 2004;350:876-85.

4. Hanauer SB, Sandborn WJ, Rutgeerts P, *et al.* Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* 2006;130:323-33.
5. Sandborn WJ, Hanauer SB, Rutgeerts P, *et al.* Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut* 2007;56:1232-9.
6. Sandborn WJ, van Assche G, Reinisch W, *et al.* Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2012;142:257-65.
7. Sandborn WJ, Feagan BG, Stoinov S, *et al.* Certolizumab pegol for the treatment of Crohn's disease. *N Engl J Med* 2007;357:228-38.
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, *et al.* Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med* 2007;357:239-50.
9. Sandborn WJ, Feagan BG, Marano C, *et al.* Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014;146:96-109.